A pharmaceutical composition and its preparation method and application

Through the LNP composition of two-component cationic lipids, the encapsulation rate and purity of nucleic acid drugs are improved, and the shortcomings of the existing LNP system in terms of cytotoxicity and target cell selectivity are solved, and more efficient target gene inhibition and Cell survival rate.

CN118576568BActive Publication Date: 2024-11-26BEIJING YUEKANGKECHUANG PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411070139.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-26
Estimated Expiration
2044-08-06

AI Technical Summary

Technical Problem

The existing LNP nucleic acid drug delivery systems have insufficient cytotoxicity and target gene inhibition efficiency, and have low selectivity and stability for target cells.

Method used

LNP nucleic acid pharmaceutical composition using two-component cationic lipids, including the first cationic lipid and the second cationic lipid, auxiliary lipid and conjugated lipid, improves the encapsulation rate of the drug by specific molar ratios and combinations. and purity, reduce cytotoxicity and enhance the effect on target cells.

Benefits of technology

A higher mRNA inhibition rate and cell survival rate of target genes are achieved, cytotoxicity is reduced, and the scope of application and stability of the drug are improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118576568B_ABST
    Figure CN118576568B_ABST
Patent Text Reader

Abstract

The present disclosure provides a pharmaceutical composition, which contains a nucleic acid molecule and a carrier for delivering the nucleic acid molecule; the carrier includes a cationic lipid, an auxiliary lipid, a neutral lipid and a conjugated lipid; the cationic lipid includes a first cationic lipid and a second cationic lipid, and the first cationic lipid and the second cationic lipid are different substances from each other. Through the above technical scheme, the present disclosure provides a pharmaceutical composition with a two-component cationic lipid, which has a uniform particle size distribution, a high encapsulation rate and purity, a wide range of applications, and acts on target cells to reduce cytotoxicity, maintain a good survival rate of cells, and a high inhibition rate of target gene mRNA.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular, to a pharmaceutical composition and a preparation method and application thereof. Background Art

[0002] Oligonucleotide drugs are short-chain nucleic acids (including deoxyribonucleotides or ribonucleotides) composed of a small number of nucleotides (about 30 or less). They treat diseases by intervening in the expression of target genes. Oligonucleotide drugs regulate post-transcriptional levels and are expected to achieve breakthroughs in special protein targets that are difficult to drug. Oligonucleotide drugs mainly include five categories: antisense oligodeoxynucleotides (ASO), small interfering RNA (siRNA), miRNA, oligonucleotide aptamers and CpG oligonucleotides.

[0003] According to different delivery technologies, nucleic acid drug delivery platforms can be divided into GalNAc conjugated delivery systems, liposome nano-delivery systems (Lipid Nanoparticles, LNPs, small molecule ligands, antibodies and other molecules) and other delivery systems (protamine, polymers, inorganic nanoparticles, exosomes, polymer matrices, viral transfection, etc.). There are two main reasons why these delivery technologies can be clinically transformed: first, chemical modification technology, which improves the stability of nucleic acid molecules by modifying them and avoids recognition by the immune system; second, delivery vectors, which can protect nucleic acids from the effects of serum nuclease activity and immune components, and determine the biodistribution of drugs. Among them, the development of delivery vectors is particularly critical. At present, in the field of RNAi pharmaceuticals, the exploration of delivery vectors mainly focuses on the development and application of GalNAc coupling and lipid nanoparticle technology. Lipid nanoparticles are solid nanoparticles containing lipid components, loaded with mRNA or siRNA, spherical, and with a particle size between 10-1000nm. Among them, negatively charged RNA combines with positively charged lipids to form smaller particles with a reverse-staggered structure, and the outer layer of the particles is wrapped by phospholipids.

[0004] In 2018, the world's first siRNA drug Patisiran was approved. It is also the first nucleic acid drug to use an LNP delivery system. The drug encapsulates siRNA in lipid nanoparticles and delivers the drug directly to the liver through intravenous infusion to prevent the body from producing pathogenic proteins. In addition to negatively charged mRNA or siRNA, LNP has four other ingredients. In the current mainstream LNP prescriptions, cationic lipids and auxiliary lipids are mostly single components: ionizable cationic phospholipids (ionizablelipids), which are the most critical excipients and the decisive factor in delivery and transfection efficiency. Because they are more easily absorbed by antigen-presenting cells, they are often used in vaccines; neutral auxiliary phospholipids, generally saturated phospholipids, can increase the phase transition temperature of cationic liposomes, support the formation of lamellar lipid bilayer structures and stabilize their structural arrangement; cholesterol, which has strong membrane fusibility, can promote mRNA intracellular uptake and cytoplasmic entry; polyethylene glycol-modified phospholipids (PEGylated lipid), located on the surface of lipid nanoparticles, can improve their hydrophilicity, avoid rapid clearance by the immune system, prevent particle aggregation, and increase stability. The use of LNP (lipid nanoparticles) and GalNAc (N-acetylgalactosamine) delivery systems to deliver oligonucleotides has important applications in the field of drug delivery. In terms of delivering oligonucleotides, LNP may solve some problems compared to the GalNAc delivery system in terms of the breadth of tissues and cell types, the efficiency of cellular uptake and internalization, the diversity of delivery, evasion of immune detection, and side effects and toxicity.

[0005] Therefore, in order to solve the defects and shortcomings of GalNAc, the most commonly used oligonucleotide drug delivery system, it is urgent to provide a breakthrough LNP nucleic acid drug. Summary of the invention

[0006] The purpose of the present disclosure is to provide a breakthrough LNP nucleic acid drug with a wide range of applications and the effects of reducing cytotoxicity, maintaining a good survival rate of cells and a high inhibition rate of target gene mRNA on target cells.

[0007] In order to achieve the above-mentioned object, in one aspect, the present disclosure provides a pharmaceutical composition, which contains a nucleic acid molecule and a carrier for delivering the nucleic acid molecule; the carrier includes a cationic lipid, a helper lipid, a neutral lipid and a conjugated lipid;

[0008] The cationic lipids include a first cationic lipid and a second cationic lipid, and the first cationic lipid and the second cationic lipid are different from each other.

[0009] Optionally, the first cationic lipid and the second cationic lipid are each selected from any one of the group consisting of YK-009, YK-501, YK-305, SM-102, ALC-0315, D-Lin-MC2-DMA, D-Lin-MC3-DMA and D-Lin-MC4-DMA;

[0010] The structural formulas of YK-009, YK-501, YK-305, SM-102, ALC-0315, D-Lin-MC2-DMA, D-Lin-MC3-DMA and D-Lin-MC4-DMA are shown below:

[0011] ,

[0012] ,

[0013] ,

[0014] ,

[0015] ,

[0016] ,

[0017] ,

[0018] .

[0019] Optionally, the first cationic lipid is YK-009 and the second cationic lipid is YK-501.

[0020] Optionally, the molar ratio of the first cationic lipid to the second cationic lipid is (1-9):(9-1), preferably (5-9):(5-1), and more preferably 7:3.

[0021] Optionally, the helper lipid includes a first helper lipid and a second helper lipid, and the first helper lipid and the second helper lipid are different from each other.

[0022] Preferably, the first helper lipid and the second helper lipid are each selected from the group consisting of cholesterol, β-sitosterol, stigmasterol and derivatives thereof. Preferably, the first helper lipid is cholesterol, and the second helper lipid is β-sitosterol.

[0023] Optionally, the molar ratio of the first helper lipid to the second helper lipid is (1-9):(9-1), preferably (3-7):(7-3), and more preferably 1:1.

[0024] Optionally, the neutral lipid is selected from any one or a combination of two or more of the group consisting of dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC) and dioleoylphosphatidylethanolamine (DOPE);

[0025] Preferably, the neutral lipid is distearoylphosphatidylcholine (DSPC).

[0026] Optionally, the conjugated lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, or a combination of two or more thereof;

[0027] Preferably, the conjugated lipid is selected from the group consisting of methoxy polyethylene glycol-dimyristoyl phosphatidylethanolamine (mPEG-DMG-2K), distearoyl phosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG2000), dimyristoylglycerol-3-methoxy polyethylene glycol 2000 (DMG-PEG2000) and methoxy polyethylene glycol ditetradecanoyl acetamide (ALC-0159), or a combination of two or more thereof;

[0028] More preferably, the conjugated lipid is methoxypolyethylene glycol-dimyristoylphosphatidylethanolamine (mPEG-DMG-2K).

[0029] Optionally, in the pharmaceutical composition, the weight ratio of the nucleic acid molecule to the cationic lipid is 1:(5-15); and

[0030] The molar ratio of the cationic lipid, the neutral lipid, the auxiliary lipid and the conjugated lipid is (25-75):(5-10):(15-65):(1.5-5); preferably 47:10:41.5:1.5.

[0031] Optionally, the nucleic acid molecule is selected from any one of the group consisting of antisense oligonucleotides (ASO), small interfering RNA (siRNA), small activating RNA (saRNA), microRNA (micRNA, miRNA, mRNA-interfering complementary RNA), oligonucleotide adaptors, and CpG oligonucleotides, or a combination of two or more thereof.

[0032] In a preferred embodiment, the molar ratio of the cationic lipid, the neutral lipid, the auxiliary lipid and the conjugated lipid is (25-75): (5-10): (15-65): (1.5-5); the first cationic lipid is YK-009, the second cationic lipid is YK-501, the auxiliary lipid is cholesterol, the neutral lipid is distearoylphosphatidylcholine (DSPC), and the conjugated lipid is methoxypolyethylene glycol-dimyristoylphosphatidylethanolamine (mPEG-DMG-2K); wherein the molar ratio of the first cationic lipid to the second cationic lipid is (1-9): (9-1).

[0033] In a preferred embodiment, the molar ratio of the cationic lipid, the neutral lipid, the auxiliary lipid and the conjugated lipid is (25-75): (5-10): (15-65): (1.5-5); the first cationic lipid is YK-009, the second cationic lipid is YK-501, the first auxiliary lipid is cholesterol, the second auxiliary lipid is β-sitosterol, the neutral lipid is distearoylphosphatidylcholine (DSPC), and the conjugated lipid is methoxypolyethylene glycol-dimyristoylphosphatidylethanolamine (mPEG-DMG-2K); wherein the molar ratio of the first cationic lipid to the second cationic lipid is (1-9): (9-1); the molar ratio of the first auxiliary lipid to the second auxiliary lipid is (1-9): (9-1).

[0034] Optionally, the pharmaceutical composition is in the form of an injection.

[0035] Optionally, the pharmaceutical composition is a nanoparticle; the particle size of the nanoparticles contained in the nanoparticle is 50-150 nm; and / or the polydispersity coefficient of the nanoparticle is not greater than 0.3.

[0036] In another aspect, the present disclosure provides a method for preparing the above-mentioned pharmaceutical composition, the preparation method comprising the following steps:

[0037] S1, mixing the cationic lipid, the auxiliary lipid, the neutral lipid and the conjugated lipid and dispersing the mixture in a first solvent to obtain a first dispersion;

[0038] S2, dispersing the nucleotide in a second solvent to obtain a second dispersion;

[0039] S3, mixing the first dispersion and the second dispersion, and encapsulating.

[0040] Optionally, the first solvent is any one selected from ethanol, acetone and N, N-dimethylformamide; and

[0041] The second solvent is citrate buffer or acetate buffer.

[0042] On the other hand, the present disclosure provides the use of the above-mentioned pharmaceutical composition in the preparation of a medicament for a disease and / or condition of a mammal in need thereof, wherein the disease and / or condition is selected from any one or a combination of two or more of the group consisting of infectious diseases, cancer, proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases and metabolic diseases.

[0043] Optionally, the disease and / or disorder is hypercholesterolemia and / or combined hyperlipidemia.

[0044] Through the above technical scheme, the present disclosure provides a pharmaceutical composition with a two-component cationic lipid, which has a uniform particle size distribution, a high encapsulation rate and purity, a wide range of applications, and has the characteristics of reducing cytotoxicity on target cells, maintaining a good survival rate of cells, and a high inhibition rate of target gene mRNA.

[0045] Other features and advantages of the present disclosure will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] The accompanying drawings are used to provide a further understanding of the present disclosure and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present disclosure but do not constitute a limitation of the present disclosure. In the accompanying drawings:

[0047] Figure 1 is the cell viability of samples containing different first cationic lipids and second cationic lipids.

[0048] Figure 2 is the cell viability of samples containing different ratios of the first cationic lipid and the second cationic lipid.

[0049] Figure 3 is the cell viability of samples with different lipid ratios in the carrier.

[0050] Figure 4 is the cell viability of samples containing different first helper lipids and second helper lipids.

[0051] Figure 5 is the cell viability of samples containing different ratios of the first helper lipid and the second helper lipid.

[0052] Figure 6 is the cell viability of samples encapsulating different oligonucleotide sequences. DETAILED DESCRIPTION

[0053] The specific embodiments of the present disclosure are described in detail below. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present disclosure, and are not used to limit the present disclosure.

[0054] In one aspect, the present disclosure provides a pharmaceutical composition comprising a nucleic acid molecule and a vector for delivering the nucleic acid molecule; the vector comprises a cationic lipid, a helper lipid, a neutral lipid, and a conjugated lipid;

[0055] The cationic lipids include a first cationic lipid and a second cationic lipid, and the first cationic lipid and the second cationic lipid are different substances from each other.

[0056] Optionally, the first cationic lipid and the second cationic lipid are any one or a combination of two or more selected from the group consisting of YK-009, YK-501, YK-305, SM-102, ALC-0315, D-Lin-MC2-DMA, D-Lin-MC3-DMA and D-Lin-MC4-DMA;

[0057] The structural formulas of YK-009, YK-501, YK-305, SM-102, ALC-0315, D-Lin-MC2-DMA, D-Lin-MC3-DMA and D-Lin-MC4-DMA are shown below:

[0058] ,

[0059] ,

[0060] ,

[0061] ,

[0062] ,

[0063] ,

[0064] ,

[0065] .

[0066] Optionally, the first cationic lipid is YK-009 and the second cationic lipid is YK-501.

[0067] Optionally, the molar ratio of the first cationic lipid to the second cationic lipid is 1:(1-9):(9-1), preferably (5-9):(5-1), and more preferably 7:3.

[0068] The present invention adopts specific two-component cationic lipids YK-009 and YK-501, which have a synergistic effect. Compared with the compositions prepared by using single-component cationic lipids, they have a significant improvement in cell survival rate and can significantly increase cell survival rate and reduce cytotoxicity.

[0069] Optionally, the helper lipid is selected from at least one of cholesterol, β-sitosterol, stigmasterol and their derivatives;

[0070] Preferably, the helper lipid comprises a first helper lipid and a second helper lipid, and the first helper lipid and the second helper lipid are different substances from each other;

[0071] Preferably, the first helper lipid is cholesterol and the second helper lipid is β-sitosterol.

[0072] Optionally, the molar ratio of the first helper lipid to the second helper lipid is (1-9):(9-1), preferably (3-7):(7-3), and more preferably 1:1.

[0073] The present invention further screens the components and ratios of auxiliary lipids, and combines them with the above-mentioned cationic lipids to further improve the particle size uniformity of the pharmaceutical composition, increase the encapsulation rate and purity of the preparation, and the cell survival rate of the target cells, and reduce cytotoxicity.

[0074] Optionally, the neutral lipid is any one or a combination of two or more selected from the group consisting of dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC) and dioleoylphosphatidylethanolamine (DOPE);

[0075] Preferably, the neutral lipid is distearoylphosphatidylcholine (DSPC).

[0076] Optionally, the conjugated lipid is any one or a combination of two or more selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol;

[0077] Preferably, the conjugated lipid is any one or a combination of two or more selected from the group consisting of methoxy polyethylene glycol-dimyristoyl phosphatidylethanolamine (mPEG-DMG-2K), distearoyl phosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG2000), dimyristoyl glycerol-3-methoxy polyethylene glycol 2000 (DMG-PEG2000) and methoxy polyethylene glycol ditetradecanoyl acetamide (ALC-0159);

[0078] More preferably, the conjugated lipid is methoxypolyethylene glycol-dimyristoylphosphatidylethanolamine (mPEG-DMG-2K).

[0079] Optionally, in the pharmaceutical composition, the weight ratio of the nucleic acid molecule to the cationic lipid is 1:(5-15);

[0080] In the carrier, the molar ratio of the cationic lipid, the neutral lipid, the auxiliary lipid and the conjugated lipid is (25-75): (5-10): (15-65): (1.5-5); preferably 47:10:41.5:1.5.

[0081] Optionally, the nucleic acid molecule is any one selected from antisense oligonucleotides (ASO), small interfering RNA (siRNA), small activating RNA (saRNA), micro RNA (micRNA, miRNA mRNA-interfering complementary RNA), oligonucleotide adaptors and CpG oligonucleotides.

[0082] In a preferred embodiment, the molar ratio of the cationic lipid, the neutral lipid, the auxiliary lipid and the conjugated lipid is (25-75): (5-10): (15-65): (1.5-5); the first cationic lipid is YK-009, the second cationic lipid is YK-501, the auxiliary lipid is cholesterol, the neutral lipid is distearoylphosphatidylcholine (DSPC), and the conjugated lipid is methoxypolyethylene glycol-dimyristoylphosphatidylethanolamine (mPEG-DMG-2K); wherein the molar ratio of the first cationic lipid to the second cationic lipid is (1-9): (9-1).

[0083] In a preferred embodiment, the molar ratio of the cationic lipid, the neutral lipid, the auxiliary lipid and the conjugated lipid is (25-75): (5-10): (15-65): (1.5-5); the first cationic lipid is YK-009, the second cationic lipid is YK-501, the first auxiliary lipid is cholesterol, the second auxiliary lipid is β-sitosterol, the neutral lipid is distearoylphosphatidylcholine (DSPC), and the conjugated lipid is methoxypolyethylene glycol-dimyristoylphosphatidylethanolamine (mPEG-DMG-2K); wherein the molar ratio of the first cationic lipid to the second cationic lipid is (1-9): (9-1); the molar ratio of the first auxiliary lipid to the second auxiliary lipid is (1-9): (9-1).

[0084] Optionally, the pharmaceutical composition is in the form of an injection.

[0085] Optionally, the pharmaceutical composition is a nanoparticle; the particle size of the nanoparticle is 50-150 nm; and / or the polydispersity coefficient of the nanoparticle is not greater than 0.3.

[0086] In another aspect, the present disclosure provides a method for preparing the above-mentioned pharmaceutical composition, the preparation method comprising the following steps:

[0087] S1, mixing the cationic lipid, auxiliary lipid, neutral lipid and conjugated lipid and dispersing the mixture in a first solvent to obtain a first dispersion;

[0088] S2, dispersing the nucleotide in a second solvent to obtain a second dispersion;

[0089] S3, mixing the first dispersion and the second dispersion, and encapsulating.

[0090] Optionally, the first solvent is an organic solvent selected from any one of ethanol, acetone and N, N-dimethylformamide;

[0091] The second solvent is an inorganic solvent selected from any one of a citrate buffer and an acetate buffer.

[0092] On the other hand, the present disclosure provides the use of the above-mentioned pharmaceutical composition in the preparation of a medicament for a disease and / or condition of a mammal in need thereof, wherein the disease and / or condition is any one selected from infectious diseases, cancer, proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases, and metabolic diseases.

[0093] Optionally, the disease and / or disorder is hypercholesterolemia and / or combined hyperlipidemia.

[0094] The present disclosure is further described in detail by way of examples. The raw materials used in the examples can all be obtained through commercial sources.

[0095] Instruments and reagents in the embodiment: Qingke 192 P model DNA / RNA automatic synthesizer, whose solid phase carrier is a universal carrier of cross-linked polystyrene beads, model Primer support 5G Unylinker 350 (cytiva manufacturer). Sources of drugs or preparations: cationic lipids; YK-009 (prepared with reference to CN 114044741A); cationic lipids; YK-501 (prepared with reference to CN116082275A); neutral lipids: distearoylphosphatidylcholine DSPC (purchased from Japan Seika Co., Ltd.); auxiliary lipids: cholesterol (purchased from Japan Seika Co., Ltd.); auxiliary lipids: β-sitosterol (purchased from Wuhan Tianzhi Biotechnology Co., Ltd.); conjugated lipids: mPEG-DMG-2K (purchased from Xiamen Sinobond Biotechnology Co., Ltd.).

[0096] Example 1

[0097] This example discloses a method for preparing a pharmaceutical composition:

[0098] (1) Preparation of oligonucleotide YKYY015:

[0099] A double-stranded RNAi agent for reducing the expression of PCSK9 was prepared, comprising an oligonucleotide duplex consisting of a sense strand and an antisense strand pair, the sequence of which is shown in Table 1, and the nucleotide abbreviations are shown in Table 2:

[0100] Table 1

[0101]

[0102] Table 2

[0103]

[0104] Preparation method:

[0105] According to the nucleotide monomer concentration of 0.15M, acetonitrile was used to prepare the following nucleotide monomer solutions: DMT-A-OMe phosphoramidite monomer (Formula 1), DMT-C-OMe phosphoramidite monomer (Formula 2), DMT-G-OMe phosphoramidite monomer (Formula 3), DMT-U-OMe phosphoramidite monomer (Formula 4), DMT-AF phosphoramidite monomer (Formula 5), ​​DMT-CF phosphoramidite monomer (Formula 6), DMT-GF phosphoramidite monomer (Formula 7) and DMT-UF phosphoramidite monomer (Formula 8).

[0106]

[0107]

[0108]

[0109] Prepared by the following steps:

[0110] (1) Deprotection: Use 3% dichloroacetic acid toluene solution as a deprotection reagent to remove the DMT protecting group, and then use acetonitrile for washing;

[0111] (2) Coupling: Use 0.25 M 5-ethylthiotetrazolyl as an activating agent to couple the acetonitrile solution of each nucleotide monomer, and then rinse with acetonitrile;

[0112] (3) Oxidation / sulfurization:

[0113] According to the specific arrangement order of the nucleotides of the forward / antisense strands, when it is necessary to connect the phosphates shown in Table 2, an oxidation step is performed: 0.05 M iodine in pyridine / water (90 / 10) solution is used as an oxidant for oxidation, and then acetonitrile is used for washing; when it is necessary to connect the thiophosphates shown in Table 2, a sulfurization step is performed: 3% hydrogenated xanthine in pyridine solution is used as a sulfurizing agent for sulfurization, and then acetonitrile is used for washing;

[0114] (4) Hydroxyl protection: 10% acetic anhydride tetrahydrofuran solution (CAP A) or tetrahydrofuran / pyridine / nitromethylimidazole 74 / 10 / 16 (v / v / v) (CAP B) was used as a hydroxyl protecting agent for hydroxyl protection, followed by rinsing with acetonitrile;

[0115] Repeat the above steps, synthesize one by one according to the specific arrangement order of nucleotides in each sequence, and obtain a fully protected product;

[0116] (5) Use 3% dichloroacetic acid toluene solution as a deprotection reagent to remove the DMT protecting group of the last nucleotide, and then use acetonitrile for washing;

[0117] (6) Ammonolysis and purification: The solid phase carrier is transferred to a reactor, concentrated aqueous ammonia (25-18%) is added, and the ammonolysis is maintained at 60°C for 12 h. The system is cooled to room temperature and the mixture is transferred to a filter press. The mixture is eluted with a mixed solution of purified water and ethanol. The filtrates are combined, passed through a chromatography column, concentrated, and freeze-dried to obtain the product.

[0118] (7) Annealing: Mix the purified sense strand and antisense strand in a 1:1 ratio, heat to 95°C and keep for 3 min, then slowly cool to room temperature to form a double strand;

[0119] The prepared product YKYY015, a double-stranded RNAi agent, had a purity of 97.4%; the measured molecular weight was 14493.52.

[0120] Preparation of pharmaceutical composition:

[0121] The pharmaceutical composition is an injection, which is composed of a LNP delivery system encapsulating the prepared YKYY015. The LNP delivery carrier is composed of a first cationic lipid, a second cationic lipid, a neutral lipid, a first auxiliary lipid, a second auxiliary lipid and a conjugated lipid. The molar percentage of the first cationic lipid YK-009 and the second cationic lipid YK-501 in the carrier is 47 mol% (the molar ratio of YK-009 to YK-501 is 7:3); the molar percentage of the neutral lipid DSPC in the carrier is 10 mol%; the molar percentage of the first auxiliary lipid cholesterol and the second auxiliary lipid β-sitosterol in the carrier is 41.5 mol% (the molar ratio of cholesterol to β-sitosterol is 1:1); the molar percentage of the conjugated lipid mPEG-DMG-2K in the carrier is 1.5 mol%. In addition, the mass ratio of YKYY015 to the two-component cationic lipid is 1:10 (i.e., the mass of YKYY015: the total mass of YK-009 and YK-501 = 1:10).

[0122] The preparation process of the above-mentioned pharmaceutical composition is as follows:

[0123] The first cationic lipid YK-009, the second cationic lipid YK-501, distearoylphosphatidylcholine DSPC, the first auxiliary lipid cholesterol, the second auxiliary lipid β-sitosterol and mPEG-DMG-2K were dissolved in anhydrous ethanol at a molar percentage of 32.9 mol%: 14.1 mol%: 10 mol%: 20.75 mol%: 20.75 mol%: 1.5 mol% to prepare an organic phase. The oligonucleotide YKYY015 prepared above was dissolved in pH 4.0 citrate buffer to prepare an aqueous phase. The organic phase and the aqueous phase were quickly mixed in a microfluidic device (manufacturer: Precision NanoSystems;) for encapsulation (the ratio of the organic phase and the aqueous phase inlet speed was 1:3, the total inlet speed was 12 mL / min, chip model: Ignite NxGen). After the encapsulation, the sample was placed in a dialysis box (Slide-A-LyzerTM G3, 20K The sample was dialyzed overnight in Tris-HCl buffer (12 g of Tris-HCl and 2.5 g of Tris were dissolved in an appropriate amount of water for injection, the volume was made up to 5 L with water for injection, and the solution was dissolved by stirring to obtain Tris-HCl buffer) to obtain a sample encapsulated with cationic lipid / DSPC / cholesterol / mPEG-DMG-2K. After 12 h of dialysis, the liquid was collected and stored at 2-8 °C.

[0124] Comparative Examples 1-8

[0125] Comparative Examples 1-8 used the same method and formula as Example 1, except that the first cationic lipid and the second cationic lipid were replaced with the components and proportions shown in Table 3 to prepare pharmaceutical composition samples.

[0126] Table 3 Components and their ratios

[0127]

[0128] Example 2

[0129] Examples 2-1 to 2-5 used the same method and formula as Example 1, replacing the first cationic lipid and the second cationic lipid with the components shown in Table 4 to prepare a pharmaceutical composition.

[0130] Table 4 Components and ratios

[0131]

[0132] Example 3

[0133] In Examples 3-1 to 3-4, the same method and formula as in Example 1 were used, and the ratio of the first cationic lipid to the second cationic lipid was replaced with the ratio described in Table 5 to prepare a pharmaceutical composition.

[0134] Table 5 Components and ratios

[0135]

[0136] Example 4

[0137] The same method and formula as in Example 1 were used in the pharmaceutical compositions of Examples 4-1 to 4-6, and the ratios were replaced as shown in Table 6: wherein ① the molar ratio of the two different cationic lipids remained unchanged, YK-009:YK-501=7:3; ② the molar ratio of the two different auxiliary lipids remained unchanged, cholesterol:β-sitosterol=1:1.

[0138] Table 6 Components and ratios

[0139]

[0140] Example 5

[0141] The preparation methods and formulations of Examples 5-1 to 5-4 are the same as those of Example 1, except that the two-component auxiliary lipid (cholesterol and β-sitosterol) is replaced by the auxiliary lipid shown in Table 7.

[0142] Table 7 Components and ratios

[0143]

[0144] Example 6

[0145] On the basis of Example 1, the molar ratio of cholesterol to β-sitosterol was changed from 1:1 to 1:9, 3:7, 7:3 and 9:1, respectively, as shown in Table 8.

[0146] Table 8 Components and ratios

[0147]

[0148] Example 7

[0149] This example uses the LNP formulation of Example 1 for delivering other types of oligonucleotide drugs.

[0150] On the basis of Example 1, the oligonucleotide sequence in the drug prepared in step 1) of Example 1 was replaced with other sequences, that is, the sense chain was SEQ ID NO. 3CUUUUGUAACUUGAAGAUAUU, and the antisense chain was SEQ ID NO. 4AAUAUCUUCAAGUUACAAAAGCA, and the other prescription proportions and processes remained unchanged.

[0151] Comparative Example 9

[0152] This comparative example does not use the LNP delivery system of Example 1, but directly dissolves YKYY015 in Tris-HCl buffer to obtain the target solution.

[0153] Test Example 1

[0154] This test example is used to measure the physicochemical properties of the pharmaceutical compositions prepared in the above examples and comparative examples.

[0155] (1) Particle size and particle size distribution index (PDI): Particle size and PDI were measured using dynamic light scattering (DLS) at 25 ± 1 °C in a nano-laser particle size analyzer (manufacturer: MALVERN; model: ZSU3305). 60 μL of sample was taken and placed in a quartz micro-sample cell for measurement. The measurement parameters were set as shown in Table 9.

[0156] Table 9 Detection parameters

[0157]

[0158] (2) Encapsulation efficiency detection: The sample was diluted to 2.8 μg / mL, and a portion was mixed with an equal volume (50 μL) of Triton X-100 to fully break the emulsion for determination of the total siRNA concentration. The other portion was mixed with an equal volume (50 μL) of TE (Tris-EDTA) for determination of the free unencapsulated siRNA concentration. The samples with TE (Tris-EDTA) and Triton X-100 were incubated at 37°C for a certain period of time, and then 100 μL of Ribogreen reagent diluted 200 times was added. After centrifugation to remove bubbles, the fluorescence value was measured using a multifunctional microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 528 nm, and the plate was read.

[0159] (3) Purity testing:

[0160] (3-1) Determination by high performance liquid chromatography (non-denaturing IP-RP-HPLC method, Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0512):

[0161] Test solution: accurately measure an appropriate amount of this product, add 1×PBS (0.01mol / L phosphate buffered saline) to dilute to prepare a solution containing 1mg of YKYY015 per 1mL; system suitability solution: take an appropriate amount of YKYY015 reference substance (or typical test substance) and antisense strand reference substance (or typical test substance), add 1×PBS to dilute to prepare a solution containing 1mg of YKYY015 and 0.1mg of antisense strand per 1mL; sensitivity solution: accurately pipette an appropriate amount of system suitability solution, add 1×PBS to dilute to prepare a solution containing 0.002mg of YKYY015 per 1mL; chromatographic conditions: use octadecyl bonded silica gel as filler (XbridgeOligonucleotide BEH C18, 130Å, 2.5μm, 4.6×50mm or equivalent) column; mobile phase A: aqueous solution containing 120mmol hexafluoroisopropanol, 15mmol dibutylamine, and 1mmol disodium ethylenediaminetetraacetate (EDTA·2Na) per 1L; mobile phase B: acetonitrile-methanol (30:70), gradient elution according to Table 10. Flow rate: 0.30mL / min; detection wavelength: 260nm; column temperature: 10℃; injection volume: 3μL; sample tray temperature: 5℃.

[0162] Table 10 Mobile phase ratio

[0163]

[0164] System suitability requirements: In the system suitability solution chromatogram, the separation between the YKYY015 main peak and the antisense strand peak should be greater than 3.0, the relative standard deviation of the main peak area of ​​the 6-pin system suitability solution should not be greater than 2.0%, and the relative standard deviation of the retention time should not be greater than 1.0%. In the sensitivity solution chromatogram, the signal-to-noise ratio of the main component peak height should not be less than 10.

[0165] Determination method: Accurately measure the test solution and inject it into the liquid chromatograph, and record the chromatogram; Limit: If there are impurity peaks in the chromatogram of the test solution, the purity should be not less than 90.0% calculated by the area normalization method.

[0166] (3-2) The purity was determined by high performance liquid chromatography (denaturing IP-RP-HPLC method, Chinese Pharmacopoeia 2020 Edition, Part IV, General Rules 0512).

[0167] Test solution: accurately measure an appropriate amount of this product and dilute it with water to make a solution containing 1.5 mg of YKYY015 per 1 mL; System suitability solution: accurately take an appropriate amount of YKYY015 reference substance (or typical test product) and add water to make a solution containing 1.5 mg of YKYY015 per 1 mL; Sensitivity solution: accurately pipette an appropriate amount of system suitability solution and dilute it with water to make a solution containing 0.003 mg of YKYY015 per 1 mL; Chromatographic conditions: use octadecyl bonded silica gel as filler (AcquityOligonucleotide BEH C18 130Å, 2.1mm×150mm, 1.7μm or equivalent) column; mobile phase A: aqueous solution containing 200mmol hexafluoroisopropanol and 25mmol hexylamine per 1L, mobile phase B: acetonitrile-methanol (50:50), gradient elution according to the mobile phase ratio shown in Table 11; flow rate: 0.30mL / min; detection wavelength: 260nm; column temperature: 70℃; injection volume: 2μL; sample tray temperature: 5℃.

[0168] Table 11 Mobile phase ratio

[0169]

[0170] System suitability requirements: In the system suitability solution chromatogram, the relative standard deviation of the main peak area of ​​the sense and antisense chains of the 6-pin system suitability solution should not be greater than 5.0%, and the relative standard deviation of the retention time should not be greater than 1.0%; in the sensitivity solution chromatogram, the signal-to-noise ratio of the main component peak height should not be less than 10; Determination method: Accurately measure the test solution and inject it into the liquid chromatograph, and record the chromatogram; Limit: If there are impurity peaks in the chromatogram of the test solution, the purity (the sum of the two single chains) should be calculated by the area normalization method and should not be less than 90.0%;

[0171] (3-3) Purity (denaturing IEX-HPLC method) was determined according to high performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0512); Test solution: Accurately measure an appropriate amount of this product and dilute it with water to make a solution containing 1.5 mg of YKYY015 per 1 mL; System suitability solution: Take an appropriate amount of YKYY015 reference substance (or typical test substance) and add water to make a solution containing 1.5 mg of YKYY015 per 1 mL.

[0172] Sensitivity solution: Accurately pipette an appropriate amount of system suitability solution and dilute with water to make a solution containing 0.003 mg of YKYY015 per 1 mL.

[0173] Chromatographic conditions: Anion exchange chromatography column (Dionex DNA Pac TM PA-200, 4×250mm or chromatographic column with equivalent performance); Mobile phase A: 800mL of mixed salt solution (pH8.5) (20mmol disodium hydrogen phosphate, 7mmol citric acid, 1mmol disodium ethylenediaminetetraacetic acid, pH adjusted to 8.5 with sodium hydroxide solution) and 200mL of acetonitrile per 1L; Mobile phase B: Mobile phase A solution containing 1mol / L sodium bromide, gradient elution according to Table 12. Flow rate is 1.0mL per minute; detection wavelength is 260nm; column temperature is 85℃; injection volume is 20μL; sample tray temperature is 5℃.

[0174] Table 12 Mobile phase ratio

[0175]

[0176] System suitability requirements: In the system suitability solution chromatogram, the relative standard deviation of the main peak area of ​​the sense and antisense chains of the 6-pin system suitability solution should not be greater than 5.0%, and the relative standard deviation of the retention time should not be greater than 1.0%. In the sensitivity solution chromatogram, the signal-to-noise ratio of the main component peak height should not be less than 10; Determination method: Accurately measure the test solution and inject it into the liquid chromatograph, and record the chromatogram; Limit: If there are impurity peaks in the chromatogram of the test solution, the purity (the sum of the two single chains) should be calculated by the area normalization method and should not be less than 90.0%.

[0177] The particle size, PDI, encapsulation efficiency and purity of the tested samples are shown in Table 13-14:

[0178] Table 13 Sample particle size, PDI, and encapsulation efficiency

[0179]

[0180] Table 14 Purity of the drug composition under the above three detection methods

[0181]

[0182] It can be seen from the above table that comparative examples 1-8 are all single-component cationic lipid formulations, and the results show that the YKYY015-LNP samples prepared using single-component cationic lipids YK-501, YK-305, DOTAP, DOTMA, DODAP, YK-009, D-Lin-MC2-DMA and D-Lin-MC4-DMA have a particle size of 80.5~87.6nm, a PDI of 0.02~0.04, an encapsulation efficiency of 87.9~93.6%, a purity (non-denaturing IP-RP-HPLC method) of 91.1~95.5%, a purity (denaturing IP-RP-HPLC method) of 84.6~89.6%, and a purity (denaturing IEX-HPLC method) of 87.8~94.6%.

[0183] Among them, compared with DOTMA, DOTAP, DODAP, D-Lin-MC2-DMA and D-Lin-MC4-DMA, the YKYY015-LNP samples prepared with YK-009, YK-501 and YK-305 as cationic lipids have smaller particle size (80.5-81.6nm), smaller PDI (0.02), higher encapsulation efficiency (93.2~93.6%), and higher purity (the purity of the non-denaturing IP-RP-HPLC method is 95.3~95.5%, the purity of the denatured IP-RP-HPLC method is 89.1~89.6%, and the purity of the denatured IEX-HPLC method is 94.3~94.6%).

[0184] The above results show that the pharmaceutical composition containing different single-component cationic lipids prepared in the present invention has good particle size uniformity, high encapsulation efficiency and purity, especially the YKYY015-LNP sample containing cationic lipids YK-009, YK-501 and YK-305 has a better effect.

[0185] Compared with samples prepared with YK-009 and YK-501 as single-component cationic lipids, samples prepared with two-component cationic lipids of YK-009 and YK-501 had smaller particle size and PDI, higher encapsulation efficiency and purity. However, the particle size, PDI, encapsulation efficiency and purity of samples prepared with other two-component cationic lipids were not significantly different from those of samples prepared with their respective single-component cationic lipids.

[0186] Test Example 2

[0187] This test example is used to determine the biological properties of the pharmaceutical composition prepared above.

[0188] Cytotoxicity test: 1 μg of the test sample was added to the cell culture medium of a 96-well plate. After culturing for 24 hours, 10 μL of CCK-8 reagent was added to each well. The culture plate was returned to the incubator and incubated for 1 hour. The absorbance at 450 nm was measured by an ELISA instrument. The cytotoxicity results are shown in Table 15 and Figure 1 shown.

[0189] Transfection efficiency experiment: After YKYY015-LNP was transfected into Hela cells, the relative mRNA expression of the target gene PCSK9 was detected by RT-qPCR, and the inhibition rate of PCSK9 mRNA was calculated. The results are shown in Table 16.

[0190] Table 15 Cell viability of samples prepared with different cationic lipids

[0191]

[0192] Example 1 uses a two-component cationic lipid of YK-009 and YK-501. Compared with the samples prepared in Comparative Examples 1 and 6 using YK-501 and YK-009 as single-component cationic lipids, respectively, the cell survival rate of the sample prepared by the two-component cationic lipid of Example 1 (YK-009 and YK-501) is as high as 98%, which is significantly higher than the single-component cationic lipid formula (76% and 92%). The cell survival rate of the two-component cationic lipid is increased by 22% and 6% respectively compared with the single-component cationic lipid YK-501 or YK-009, proving that the two have a good synergistic effect. The formulation of the two-component cationic lipid of YK-009 and YK-501 can significantly improve the cell survival rate and reduce cytotoxicity.

[0193] Example 2-1 uses a two-component cationic lipid of DOTMA and DOTAP, and compared with the samples prepared by using DOTAP and DOTMA as single-component cationic lipids in Comparative Examples 3 and 4, respectively, the cell survival rates are increased by 10% and 7%, respectively. Example 2-2 uses a two-component cationic lipid of DODAP and DOTMA, and compared with the samples prepared by using DODAP and DOTMA as single-component cationic lipids in Comparative Examples 5 and 4, respectively, the cell survival rates are increased by 8% and 7%, respectively. Experiments have shown that the above-mentioned two-component cationic lipid combination also exhibits a certain synergistic effect, but the synergistic effect of Example 1 (YK-009 and YK-501 two-component) is better.

[0194] On the contrary, the cell preservation rates of the two-component cationic lipids in Example 2-3 (D-Lin-MC2-DMA and D-Lin-MC4-DMA), Example 2-4 (YK-305 and YK-501) and Example 2-5 (YK-009 and YK-305) were slightly increased or showed a decreasing trend compared with the corresponding single-component cationic lipids. For example, the cell survival rate of the two-component cationic lipid in Example 2-4 was increased by 2% compared with the corresponding single-component cationic lipid YK-501 in Comparative Example 1, but was decreased by 5% compared with the single-component cationic lipid YK-305 in Comparative Example 2; no good synergistic effect was reflected.

[0195] Table 16 Inhibition rate of Hela cell PCSK9 mRNA by samples prepared with different cationic lipids

[0196]

[0197] Note: The control group is a sample that was not transfected.

[0198] The single-component cationic lipid formulas of Comparative Examples 1-8 have inhibition rates on the mRNA expression of the target gene PCSK9 ranging from 73% to 93%. Among them, the inhibition rate of YK-009 in Comparative Example 6 on the mRNA expression of the target gene PCSK9 is the highest, maintained at 93%, proving that it has a certain inhibitory effect on the mRNA expression of the target gene PCSK9.

[0199] Consistent with the results of the cytotoxicity experiment, Example 1 uses a two-component cationic lipid of YK-009 and YK-501. Compared with the samples prepared in Comparative Examples 1 and 6 using YK-501 and YK-009 as single-component cationic lipids, respectively, the sample prepared by the two-component cationic lipid of Example 1 (YK-009 and YK-501) has an inhibition rate of up to 98% on PCSK9 mRNA, which is significantly higher than the single-component cationic lipid formula (73% and 93%). The inhibition rate of the two-component cationic lipid on PCSK9 mRNA is increased by 25% and 5% respectively compared with the single-component cationic lipid YK-501 or YK-009, which proves that the two have a good synergistic effect. The formulation of the two-component cationic lipid of YK-009 and YK-501 can significantly improve the inhibition rate of PCSK9 mRNA.

[0200] On the contrary, the inhibition rate of PCSK9 mRNA by the two-component cationic lipids of Example 2-3 (D-Lin-MC2-DMA and D-Lin-MC4-DMA), Example 2-4 (YK-305 and YK-501) and Example 2-5 (YK-009 and YK-305) was slightly increased or showed a decreasing trend compared with the corresponding single-component cationic lipids. For example, the inhibition rate of PCSK9 mRNA by the two-component cationic lipid of Example 2-5 was the same as that of the corresponding single-component cationic lipid YK-305 of Comparative Example 2, but was 4% lower than that of the single-component cationic lipid YK-009 of Comparative Example 6; no synergistic effect was shown.

[0201] The above-mentioned cytotoxicity and biological activity experimental results show that the combination of specific two-component cationic lipids can show good synergistic effects, with low cytotoxicity, high cell survival rate and high inhibition rate of PCSK9 mRNA.

[0202] From the above conclusions and analysis, it can be seen that the samples prepared by two-component cationic lipids are better than those prepared by single-component cationic lipids, especially the synergistic effect of the two-component cationic lipid samples with YK-009 and YK-501 is the best. With YK-009 and YK-501 as two-component cationic lipids, the molar ratio of YK-009 to YK-501 in Example 1 was adjusted from 7:3 to 1:9, 3:7, 1:1 and 9:1, as shown in Table 17, and the particle size, dispersion coefficient, encapsulation efficiency and purity were used as evaluation indicators to judge the optimal cationic lipid ratio, and the particle size, PDI, encapsulation efficiency and purity of the samples were tested. The results are shown in Tables 18-19.

[0203] Table 17 Ratio of two-component cationic lipids

[0204]

[0205] Table 18 Comparison of particle size (nm), PDI, and encapsulation efficiency (%)

[0206]

[0207] Table 19 Purity under different detection methods

[0208]

[0209] (1) Particle size and PDI: There was no significant difference in the particle size and PDI of the samples prepared with different ratios of two-component cationic lipids (molar ratios of YK-009 to YK-501 of 1:9, 3:7, 1:1, 7:3 and 9:1), indicating that the above two-component cationic lipid ratios were suitable for the LNP delivery system encapsulating YKYY015, and the particle uniformity was good. In contrast, the particle size and PDI of Example 1 (molar ratio of YK-009 to YK-501 of 7:3), Example 3-3 (molar ratio of YK-009 to YK-501 of 1:1) and Example 3-4 (molar ratio of YK-009 to YK-501 of 9:1) were smaller, and the particle size and PDI of Example 1 (molar ratio of YK-009 to YK-501 of 7:3) were the smallest.

[0210] (2) Encapsulation efficiency: There was no significant difference in the encapsulation efficiency of samples prepared with different ratios of two-component cationic lipids (the molar ratio of YK-009 to YK-501 was 1:9, 3:7, 1:1, 7:3 and 9:1). In comparison, the encapsulation efficiency of Example 1 (the ratio of YK-009 to YK-501 was 7:3), Example 3-3 (the molar ratio of YK-009 to YK-501 was 1:1) and Example 3-4 (the molar ratio of YK-009 to YK-501 was 9:1) was higher, and the encapsulation efficiency of Example 1 (the molar ratio of YK-009 to YK-501 was 7:3) was the highest.

[0211] (3) Purity: There was no significant difference in the purity of the samples prepared with different ratios of two-component cationic lipids (the molar ratio of YK-009 to YK-501 was 1:9, 3:7, 1:1, 7:3 and 9:1). In comparison, Example 1 (the molar ratio of YK-009 to YK-501 was 7:3), Example 3-3 (the molar ratio of YK-009 to YK-501 was 1:1) and Example 3-4 (the molar ratio of YK-009 to YK-501 was 9:1) had higher purities, and Example 1 (the molar ratio of YK-009 to YK-501 was 7:3) had the highest purity.

[0212] The above results show that the YKYY015-LNP samples prepared by the method disclosed herein using different ratios of two-component cationic lipids (molar ratios of YK-009 to YK-501 of 1:9, 3:7, 1:1, 7:3 and 9:1) have good uniformity of particle size of the preparations obtained, and have higher encapsulation efficiency and purity compared with the samples prepared by single-component cationic lipids. In particular, the samples prepared by two-component cationic lipids with molar ratios of 1:1, 7:3 and 9:1 have smaller particle sizes and PDI, higher encapsulation efficiency and purity, and when the molar ratio is 7:3, the particle size and PDI are the smallest, and the encapsulation efficiency and purity are the highest.

[0213] The samples prepared by the method disclosed herein using two-component cationic lipids in different ratios (the molar ratio of YK-009 to YK-501 is 1:9, 3:7, 1:1, 7:3 and 9:1) have good uniformity in particle size of the obtained preparations, and have higher encapsulation efficiency and purity compared with the samples prepared by single-component cationic lipids. In particular, the samples prepared by two-component cationic lipids with molar ratios of 1:1, 7:3 and 9:1 have smaller particle sizes and PDI, higher encapsulation efficiency and purity, and when the molar ratio is 7:3, the particle size and PDI are the smallest, and the encapsulation efficiency and purity are the highest. Specifically:

[0214] The samples prepared with different ratios of two-component cationic lipids (the molar ratio of YK-009 to YK-501 was 1:9, 3:7, 1:1, 7:3 and 9:1) had particle sizes of 75.8nm~78.7nm, PDI of 0.02~0.03, encapsulation efficiency of 94.6%~95.5%, purity (non-denaturing IP-RP-HPLC method) of 95.6%~97.2%, purity (denaturing IP-RP-HPLC method) of 89.6%~91.2%, and purity (denaturing IEX-HPLC method) of 95.1%~96.8%. Among them, the samples prepared with two-component cationic lipids with molar ratios of 1:1, 7:3 and 9:1 had smaller particle size and PDI (particle size was 75.8nm~76.5nm, PDI was 0.02), higher encapsulation efficiency and purity (encapsulation efficiency was 94.9%~95.9%, non-denatured IP-RP-HPLC purity was 96.5%~97.2%, denatured IP-RP-HPLC purity was 90.8%~91.2%, and denatured IEX-HPLC purity was 96.2%~96.8%). Especially when the molar ratio was 7:3, the particle size and PDI were the smallest (particle size was 75.8nm, PDI was 0.02), and the encapsulation efficiency and purity were the highest (encapsulation efficiency was 95.9%, non-denatured IP-RP-HPLC purity was 97.2%, denatured IP-RP-HPLC purity was 91.2%, and denatured IEX-HPLC purity was 96.8%).

[0215] Cytotoxicity assay: Example 1 and Example 3-1 to Example 3-4 were added to the cell solution to examine the cytotoxicity. The results are shown in Tables 20 and 21. Figure 2 As shown:

[0216] Table 20 Cell viability of samples prepared with different cationic lipid ratios

[0217]

[0218] The above results show that the cell survival rates of the samples prepared in Example 1 (the molar ratio of YK-009 to YK-501 is 7:3), Example 3-1 (the molar ratio of YK-009 to YK-501 is 1:9), Example 3-2 (the molar ratio of YK-009 to YK-501 is 3:7), Example 3-3 (the molar ratio of YK-009 to YK-501 is 1:1) and Example 3-4 (the molar ratio of YK-009 to YK-501 is 9:1) are 92-98%. It can be seen from the data that when the molar ratio of the two cationic lipids YK-009 and YK-501 is (1-9): (9-1), the cell survival rate is good. Under the above two cationic lipid ratio conditions, the synergistic effect is good and the cytotoxicity is small. Among them, when the molar ratio of YK-009 to YK-501 is 7:3, the cell survival rate is 98%, the cytotoxicity is minimal, and the synergistic effect is optimal.

[0219] Biological activity: After Example 1 and Example 3-1 to Example 3-4 were transfected into Hela cells at a concentration of 5 nM, the relative mRNA expression of the target gene PCSK9 was detected by RT-qPCR, and the inhibition rate of each transfection concentration compound on PCSK9 mRNA was calculated. The results are shown in Table 21 below.

[0220] Table 21 Inhibition rate of Hela cell PCSK9 mRNA by samples prepared with different cationic lipid ratios

[0221]

[0222] Note: The control group is a sample that was not transfected.

[0223] From the results, it can be seen that there is no significant difference in the inhibition rate of PCSK9 mRNA among the samples prepared in Example 1 and Example 3-1 to Example 3-4; the inhibition rate of PCSK9 mRNA does not change significantly when YKYY015-LNP samples with different ratios of two-component cationic lipids are prepared by the method disclosed in the present invention, and the inhibition rate of YKYY015-LNP samples prepared with different ratios of two-component cationic lipids is relatively high (95%-98%), especially in Example 1 (7:3), Example 3-3 (1:1) and Example 3-4 (9:1), the inhibition rate is the highest (96%-98%).

[0224] Test Example 3

[0225] This test example is used to determine the effects of different lipid ratios on its particle size, PDI, encapsulation efficiency, purity, cytotoxicity and biological activity. The lipid ratios are shown in Table 22. The particle size, PDI, encapsulation efficiency and purity of the tested samples are shown in Tables 23-24. The cell survival rates of different lipid ratios are shown in Table 25.

[0226] Table 22 Different cationic lipids of siRNA-LNP

[0227]

[0228] Table 23 Comparison of particle size (nm), PDI, and encapsulation efficiency (%)

[0229]

[0230] Table 24 Purity under different detection methods

[0231]

[0232] Example 1 (47:10:41.5:1.5) has the smallest particle size and PDI, and the largest encapsulation rate and purity; Example 4-1 (40:10:48.5:1.5) and Example 4-2 (35:10:53.5:1.5) have slightly larger particle size and PDI, and slightly lower encapsulation rate and purity; Example 4-3 (75:5:15:5) and Example 4-4 (25:5:65:5) have larger particle size and PDI, and lower encapsulation rate and purity; Example 4-5 (15:10:73.5:1.5) and Example 4-6 (85:10:3.5:1.5) have the largest particle size and PDI, and the lowest encapsulation rate and purity.

[0233] Table 25 Cell survival rate at different lipid ratios

[0234]

[0235] Samples with different molar percentages of cationic lipids, neutral lipids, auxiliary lipids and conjugated lipids in LNP were added to cell solutions to investigate cytotoxicity. The results are shown in Figure 3 shown.

[0236] The samples prepared in Example 1 (47:10:41.5:1.5), Example 4-1 (40:10:48.5:1.5), and Example 4-2 (35:10:53.5:1.5) had the highest cell survival rates; the cell survival rates of Example 4-3 (75:5:15:5) and Example 4-4 (25:5:65:5) were relatively low, and the cell survival rates of Example 4-5 (15:10:73.5:1.5) and Example 4-6 (85:10:3.5:1.5) were the lowest;

[0237] The YKYY015-LNP samples prepared using different lipid ratios using the method disclosed in the present invention had high cell survival rates (87%~98%), especially the samples prepared at 47:10:41.5:1.5, 40:10:48.5:1.5, and 35:10:53.5:1.5, which had the highest cell survival rates (95%~98%). Therefore, the method disclosed in the present invention is suitable for YKYY015-LNP samples with different LNP ratios.

[0238] Biological activity: After Example 1 and Example 4-1 to Example 4-6 were transfected into Hela cells at a concentration of 5 nM, the relative mRNA expression of the target gene PCSK9 was detected by RT-qPCR, and the inhibition rate of each transfection concentration compound on PCSK9 mRNA was calculated. The results are shown in Table 26 below.

[0239] Table 26 Inhibition rate of Hela cell PCSK9 mRNA by samples with different lipid ratios

[0240]

[0241] Note: The control group is a sample that was not transfected.

[0242] Samples with different molar percentages of cationic lipids, neutral lipids, auxiliary lipids and conjugated lipids in LNP were transfected into Hela cells to investigate the inhibition rate of PCSK9 mRNA. The results show that:

[0243] The samples prepared in Example 1 (47:10:41.5:1.5), Example 4-1 (40:10:48.5:1.5), and Example 4-2 (35:10:53.5:1.5) had the highest inhibition rates of PCSK9 mRNA; the inhibition rates of PCSK9 mRNA in Example 4-3 (75:5:15:5) and Example 4-4 (25:5:65:5) were lower, and the inhibition rates of PCSK9 mRNA in Example 4-5 (15:10:73.5:1.5) and Example 4-6 (85:10:3.5:1.5) were the lowest.

[0244] The YKYY015-LNP samples prepared by the method of the present invention using different lipid ratios (47:10:41.5:1.5, 40:10:48.5:1.5, 35:10:53.5:1.5, 25:5:65:5 and 75:5:15:5) had high PCSK9 mRNA inhibition rates (82%~98%), especially the samples prepared at 47:10:41.5:1.5, 40:10:48.5:1.5, and 35:10:53.5:1.5, which had the highest cell survival rates (92%~98%). Therefore, the method of the present invention is suitable for YKYY015-LNP samples with different LNP ratios.

[0245] Test Example 4

[0246] This test example is used to determine the effects of different types of auxiliary lipids on sample quality in the above examples, with sample particle size, PDI, encapsulation efficiency, purity, cytotoxicity and biological activity as evaluation indicators. The types of auxiliary lipids are shown in Table 27, and the sample particle size, PDI, encapsulation efficiency and purity are tested. The results are shown in Table 28. The purity of the samples under different detection methods is shown in Table 29, the cytotoxicity is shown in Table 30, and the biological activity is shown in Table 31.

[0247] Table 27 Types of auxiliary lipids

[0248]

[0249] Table 28 Physical and chemical properties

[0250]

[0251] Table 29 Purity under different detection methods

[0252]

[0253] The data show that compared with samples prepared with single-component auxiliary lipids, samples prepared with two-component auxiliary lipids have smaller particle size and PDI, and higher encapsulation rate and purity; and among samples prepared with different two-component cationic lipids, samples prepared with a combination of cholesterol and β-sitosterol have smaller particle size and PDI, and higher encapsulation rate and purity.

[0254] Table 30 Cell survival rate of different auxiliary lipid types

[0255]

[0256] The data show that compared with the samples prepared with a single-component auxiliary lipid, the cell survival rate of the samples prepared with a two-component auxiliary lipid is higher. Compared with the samples using only a single-component auxiliary lipid, the cell survival rate is increased by 5% to 6%; compared with the samples using other two-component auxiliary lipid combinations (such as Example 5-4), the cell survival rate is increased by 3% (the results are shown in Figure 4 as shown).

[0257] Table 31 Inhibition rate of Hela cell PCSK9 mRNA by samples prepared with different types of auxiliary lipids

[0258]

[0259] Note: The control group is a sample that was not transfected.

[0260] The results show that compared with the samples prepared by single-component auxiliary lipids, the PCSKmRNA inhibition rate of the samples prepared by two-component auxiliary lipids is higher. And among the different two-component auxiliary lipids, the PCSKmRNA inhibition rate of the samples prepared by the combination of cholesterol and β-sitosterol is higher.

[0261] This test example further determined the difference in quality of samples containing two-component auxiliary lipids in different proportions. Cholesterol and β-sitosterol were used as two-component auxiliary lipids. The molar ratio of cholesterol and β-sitosterol in Example 1 was adjusted from 1:1 to 1:9, 3:7, 7:3 and 9:1. The particle size, dispersion coefficient, encapsulation efficiency and purity were used as evaluation indicators to judge the optimal cationic lipid ratio, as shown in Table 32. The physicochemical properties are shown in Table 33. The purity of the sample under different detection methods is shown in Table 34. Example 1 and Example 6-1 to Example 6-4 were added to the cell solution to examine the cytotoxicity, and the results are shown in Tables 35 and 36. Figure 5 As shown; after Example 1 and Example 6-1 to Example 6-4 were transfected into Hela cells at a concentration of 5 nM, the relative mRNA expression of the target gene PCSK9 was detected by RT-qPCR, and the inhibition rate of each transfection concentration compound on PCSK9 mRNA was calculated. The results are shown in Table 36.

[0262] Table 32 Ratio of two-component auxiliary lipids

[0263]

[0264] Table 33 Comparison of particle size (nm), PDI and encapsulation efficiency (%)

[0265]

[0266] Table 34 Purity under different detection methods

[0267]

[0268] Table 35 Cell viability of samples prepared with different auxiliary lipid ratios

[0269]

[0270] The results show that when the molar ratio of cholesterol to β-sitosterol is in the range of (1-9):(9-1), the cell survival rate of the prepared samples is relatively high. However, in comparison, when the molar ratio of cholesterol to β-sitosterol is 1:1, 3:7 and 7:3, the cell survival rate of the prepared samples is the highest.

[0271] Table 36 Inhibition rate of Hela cell PCSK9 mRNA by samples prepared with different auxiliary lipid ratios

[0272]

[0273] Note: The control group is a sample that was not transfected.

[0274] The results show that when the molar ratio of cholesterol to β-sitosterol is in the range of (1-9): (9-1), the PCSK9 mRNA inhibition rate of the prepared samples is relatively high. However, in comparison, when the molar ratio of cholesterol to β-sitosterol is 1:1, 3:7 and 7:3, the PCSK9 mRNA inhibition rate of the prepared samples is the highest.

[0275] Test Example 5

[0276] This test example was used to determine the suitability of the LNP delivery vehicle for different oligonucleotide sequences.

[0277] Experiments were designed to examine the applicability of the delivery system prepared by the prescription and process of the present disclosure to different oligonucleotide sequences, using particle size, PDI, encapsulation efficiency, purity, cytotoxicity and biological activity as evaluation indicators. The nucleotide sequence is shown in Table 37, the sample particle size, PDI and encapsulation efficiency are shown in Table 38, and the sample purity under different detection methods is shown in Table 39. The samples of Example 1 and Example 7 were added to the cell solution to examine the cytotoxicity, and the results are shown in Tables 40 and 41. Figure 6 As shown; After Example 1 and Example 7 were transfected into Hela cells at a concentration of 5 nM, the relative mRNA expression of the target gene PCSK9 was detected by RT-qPCR, and the inhibition rate of each transfection concentration compound on PCSK9 mRNA was calculated, and the results are shown in Table 41.

[0278] Table 37 Oligonucleotide sequence

[0279]

[0280] Table 38 Comparison of particle size (nm) and PDI encapsulation efficiency (%)

[0281]

[0282] Table 39 Purity under different detection methods

[0283]

[0284] From the data, it can be seen that when the LNP delivery system is prepared using the prescription and process in this patent, there is no significant difference in particle size, PDI, encapsulation rate and purity after encapsulating different oligonucleotide sequences, which proves that this prescription and process are stable and reliable and suitable for oligonucleotide samples of different sequences.

[0285] Table 40 Cell viability of samples prepared with different oligonucleotide sequences

[0286]

[0287] The data show that after different oligonucleotide sequences are encapsulated by the LNP delivery system prepared by the present disclosure, there is no significant difference in the cell survival rate, which proves that their cytotoxicity is consistent and the delivery system is suitable for different oligonucleotide sequences.

[0288] Table 41 Inhibition rate of samples prepared with different oligonucleotide sequences on Hela cell PCSK9 mRNA

[0289]

[0290] Note: The control group is a sample that was not transfected.

[0291] It can be seen from the data that after encapsulating different oligonucleotide sequences using the LNP delivery system prepared by the present invention, there is no significant difference in the PCSKmRNA inhibition rate and the inhibition rate remains at a very high level. Therefore, this delivery system is suitable for different oligonucleotide sequences.

[0292] Test Example 6

[0293] The effects of the disclosed method and the method of directly dissolving YKYY015 without using a delivery system on product quality were investigated. The prepared samples were placed at 2-8°C for 30 days. The test results are shown in Tables 42-44.

[0294] Table 42 Purity (Non-denaturing IP-RP-HPLC method, %)

[0295]

[0296] Table 43 Purity (denaturing IP-RP-HPLC method, %)

[0297]

[0298] Table 44 Purity (denaturing IEX-HPLC method, %)

[0299]

[0300] It can be seen from the data that the purity changes of Example 1 were controlled within 0.1-0.3% within 30 days at room temperature, with almost no change. Compared with Example 1, Comparative Example 9 was placed at 2-8°C for 30 days, and each purity showed a significant downward trend, with the purity (non-denaturing IP-RP-HPLC method) decreasing from 97.0% to 68.1%, the purity (denaturing IP-RP-HPLC method) decreasing from 90.1% to 60.5%, and the purity (denaturing IEX-HPLC method) decreasing from 95.8% to 66.8%. The drug purity showed a significant downward trend, poor stability, and could not be used for subsequent drug preparation.

[0301] The preferred embodiments of the present disclosure are described in detail above; however, the present disclosure is not limited to the specific details in the above embodiments. Within the technical concept of the present disclosure, a variety of simple modifications can be made to the technical solution of the present disclosure, and these simple modifications all fall within the protection scope of the present disclosure.

[0302] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present disclosure will not further describe various possible combinations.

[0303] In addition, various embodiments of the present disclosure may be arbitrarily combined, and as long as they do not violate the concept of the present disclosure, they should also be regarded as the contents disclosed by the present disclosure.

Claims

1. A pharmaceutical composition, characterized in that The pharmaceutical composition contains a nucleic acid molecule and a carrier for delivering the nucleic acid molecule; the carrier includes a cationic lipid, an auxiliary lipid, a neutral lipid and a conjugated lipid; Wherein, the cationic lipid comprises a first cationic lipid and a second cationic lipid, and the first cationic lipid and the second cationic lipid are different from each other; the helper lipid comprises a first helper lipid and a second helper lipid, and the first helper lipid and the second helper lipid are different from each other; The first cationic lipid is YK-009, and the second cationic lipid is YK-501; the first helper lipid is cholesterol, and the second helper lipid is β-sitosterol; The structural formulas of YK-009 and YK-501 are shown below: 、 ; The molar ratio of the first cationic lipid to the second cationic lipid is (1-9): (9-1); The molar ratio of the first helper lipid to the second helper lipid is (1-9): (9-1); The weight ratio of the nucleic acid molecule to the cationic lipid is 1:(5-15); and The molar ratio of the cationic lipid, the neutral lipid, the auxiliary lipid and the conjugated lipid is (25-75):(5-10):(15-65):(1.5-5).

2. The pharmaceutical composition according to claim 1, wherein The neutral lipid is selected from any one or a combination of two or more of the group consisting of dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC) and dioleoylphosphatidylethanolamine (DOPE).

3. The pharmaceutical composition according to claim 1, wherein The neutral lipid is distearoylphosphatidylcholine (DSPC).

4. The pharmaceutical composition according to claim 1, wherein The conjugated lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol, or a combination of two or more thereof.

5. The pharmaceutical composition according to claim 4, wherein The conjugated lipid is selected from any one of the group consisting of methoxypolyethylene glycol-dimyristoylphosphatidylethanolamine (mPEG-DMG-2K), distearoylphosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG2000), dimyristoylglycerol-3-methoxypolyethylene glycol 2000 (DMG-PEG2000) and methoxypolyethylene glycol ditetradecanoyl acetamide (ALC-0159), or a combination of two or more thereof.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein The nucleic acid molecule is selected from any one or a combination of two or more of the group consisting of antisense oligonucleotides, small interfering RNAs, small activating RNAs, microRNAs, oligonucleotide aptamers and CpG oligonucleotides.

7. The pharmaceutical composition according to any one of claims 1 to 5, wherein The dosage form of the pharmaceutical composition is injection.

8. The pharmaceutical composition according to claim 7, wherein The pharmaceutical composition is a nanoparticle; the particle size of the nanoparticles contained in the nanoparticle is 50-150 nm; and / or, The polydispersity coefficient of the nanoparticles is no greater than 0.

3.

9. A method for preparing the pharmaceutical composition according to any one of claims 1 to 8, comprising the following steps: S1, mixing the cationic lipid, the auxiliary lipid, the neutral lipid and the conjugated lipid and dispersing the mixture in a first solvent to obtain a first dispersion; S2, dispersing the nucleic acid molecules in a second solvent to obtain a second dispersion; S3, mixing the first dispersion and the second dispersion, and encapsulating.

10. The preparation method according to claim 9, wherein: The first solvent is selected from any one of the group consisting of ethanol, acetone and N, N-dimethylformamide; and The second solvent is citrate buffer or acetate buffer.

11. Use of the pharmaceutical composition according to any one of claims 1 to 10 in the preparation of a medicament for a disease and / or condition in a mammal in need thereof, wherein the disease and / or condition is selected from any one or a combination of two or more of the group consisting of infectious diseases, cancer, proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases and metabolic diseases.

12. The use according to claim 11, wherein: The disease and / or condition is hypercholesterolemia and / or combined hyperlipidemia.